Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2

As predicted in Post #:73549863 Medicxi is the headliner  and what gave me a laugh is the second 'highlight' bullet point .....


Starpharma’s Phase 2 clinical trial of DEP® irinotecan as monotherapy and in combination with 5-fluorouracil (5FU) and leucovorin (LV) is nearing database lock. Preparations for analysis of the full data are well underway, with the final data to be released ahead of and presented at the ASCO meeting in early June.


So suddenly we can apparently have results from a DEP phase 2 trial in less than 6 weeks and the database lock hasn't even happened yet ??  So why did the other phase 2 DEP trials and / or the Viraleze trial data take so long to release ? Remember all the excuses people made for the delays for multiple trials and yet today Starpharma are claiming that full data will be released ahead of the ASCO conference < 6 weeks .... you can't make this stuff up


A CR is looking more and more likely as it is disclosed we only have $26 million left in the bank and the SPL7013 sales revenues were a paltry $371K ... what a disaster stock